Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The week-long campaign received a record 17.691 pledges
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)